Factsheet on orthohantavirus infections - ECDC - European Union
Orthohantaviruses (formerly known as Hantavirus genus) are enveloped, segmented, single-stranded, negative-sense RNA viruses belonging to the family Hantaviridae.
www.ecdc.europa.euHere’s the latest on orthohantavirus, based on reliable sources up to May 2026.
Direct answer
- There has been ongoing global attention to orthohantaviruses, including reports of new variants and continued surveillance of outbreaks in various regions. Notably, a new orthohantavirus variant was characterized in northwestern Argentina in 2024–2025 in association with a fatal hantavirus pulmonary syndrome case outside the usual endemic area. Additionally, authoritative public health bodies summarize the lack of approved specific antivirals or vaccines for orthohantavirus infections and emphasize supportive care, with ribavirin having mixed evidence and limited efficacy in certain cases.[1][2][3]
Key recent developments
- Novel variants and case reports: A 2024–2025 report documents genetic characterization of a new orthohantavirus variant linked to a fatal HPS case in Argentina, underscoring the ongoing emergence and geographic expansion of orthohantaviruses.[1]
- Diagnostics and case definitions: Contemporary reviews and guidelines continue to outline criteria for suspected and confirmed orthohantavirus infections, highlighting serology (IgM/IgG), RT-PCR, and immunohistochemistry as diagnostic modalities, with no single universally adopted confirmatory method.[3]
- Treatment landscape: There is no approved antiviral treatment specifically for orthohantavirus infections. Management remains primarily supportive, addressing hemodynamic stability, renal function, and respiratory support as needed. Ribavirin has been used in some severe PUUV-related cases but large-scale trials show limited or inconsistent benefit, and its use remains controversial.[2]
- Surveillance and global context: Global hantavirus surveillance efforts continue to track orthohantaviruses across regions, with multiple organizations (PAHO, ECDC, WHO-linked networks) coordinating diagnostic protocols and reporting, given the zoonotic and evolving nature of these viruses.[5][3]
What this could mean for you
- If you’re monitoring orthohantavirus for public health or travel planning, expect updates on identified variants, regional case counts, and guidance on reducing rodent exposure in at-risk environments. Public health authorities frequently issue updated factsheets and surveillance summaries to reflect new data.[2][5]
- For clinicians, current guidance emphasizes early recognition of HPS and HFRS syndromes, rapid diagnostic testing when exposure is suspected, and aggressive supportive care, with awareness that antivirals are not standard-of-care across all settings.[3][2]
Illustrative context
- Outbreak trackers and surveillance dashboards (e.g., HantaRadar, Outbreak real-time trackers) provide near real-time snapshots of hantavirus activity, including case counts and regional trends, which can be helpful for rapid situational awareness though they should be corroborated with official public health sources.[4][5]
Would you like a concise, shareable briefing tailored to a specific region or audience (e.g., healthcare professionals, travelers, or public health officials), or a one-page summary with key diagnostic and management points? I can also pull the latest official factsheets from ECDC/PAHO and summarize them. If you’d like, I can include a small chart showing reported case trends by region based on publicly available surveillance data.[5][2][3]